EGFR-mutated NSCLC often exhibit compromised responses to anti-PD-(L)1 due to low PD-L1 expression, low mutational burden, and reduced lymphocyte infiltration [73,74,75]. Here, EGFR is linked to non-small cell lung carcinoma.